New adoptive gammadelta T cell therapy regulated through co-stimulatory and co-inhibitory receptor

2014 Fiscal Year Final Research Report

• Project/Area Number: 25830124
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics
• Research Institution: Hyogo Medical University
• Principal Investigator: SUZUKI TORU 兵庫医科大学, 医学部, 講師 (00441296)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: γδ T細胞 / PD-1 / 4-1BB / 副刺激

Outline of Final Research Achievements

Anti-4-1BB antibody and anti-PD-L1 antibody combined with TCR stimulation significantly up-regulated CD69 expression and inhibited activation induced cell death of γδ T cells. Although anti-4-1BB and anti-PD-L1 antibody enhanced secretion of IFNγ and perforin, granzyme compared with TCR stimulation alone, we didn’t observed significant increase. Finally, antitumor effects of γδ T cells against human bladder cancer cells didn’t increase upon co-stimulation with both antibodies. That is the reason why the ratio of 4-1BB and PD-1 positive γδ T cells decreased after 10 days of culture. Therefore, it is needed to use only 4-1BB and PD-1 positive γδ T cells for new adoptive γδ T cell therapy regulated through co-stimulatory and co-inhibitory receptor.

Free Research Field

免疫細胞療法